A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor

BACKGROUND: The discovery of receptor activator of nuclear factor‐ĸB ligand (RANKL) as the final effector in the pathogenesis of osteoporosis has led to a better understanding of bone remodeling. When RANKL binds to its receptor (RANK), osteoclastic differentiation and activation are initiated. Here...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Transl Med
Glavni autori: Ko, Young Jong, Sohn, Hong Moon, Jang, Yuria, Park, Mineon, Kim, Bora, Kim, Beomchang, Park, Jae‐Il, Hyun, Hoon, Jeong, Byeongseok, Hong, Chansik, Lim, Wonbong
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2021
Teme:
Research Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7967917/
https://ncbi.nlm.nih.gov/pubmed/33784004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ctm2.368
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items